Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen – neueste Daten aus der LIBERATE-Studie

Der Häufigkeitsgipfel der Erkrankung bei Brustkrebspatientinnen liegt im Alter zwischen 50 und 60 Jahren. Frauen in diesem Alter haben von Haus aus klimakterische Beschwerden, die die Frage nach medikamentösen Interventionen aufwerfen. Zudem führt die adjuvante Therapie bei Mammakarzinompatientinnen häufig zu vasomotorischen Symptomen und Knochenverlust. Tibolon kann beiden Symptomen vorbeugen, jedoch war der Einfluss der Substanz auf das Mammakarzinomrezidivrisiko bisher unklar. Die LIBERATE-Studie sollte zeigen, dass Tibolon bei Frauen mit klimakterischen Symptomen das Rezidivrisiko nicht erhöht. Allerdings musste die Studie vorzeitig abgebrochen werden, da das Rezidivrisiko im Tibolon-Arm nach einer medianen Behandlungsdauer von 3 Jahren im Vergleich zu Placebo signifikant erhöht war. Eine Hormonersatztherapie mit Tibolon bei klimakterischen Beschwerden kann für Patientinnen mit oder nach Mammakarzinom und auch für Patientinnen mit erhöhtem Mammakarzinomrisiko daher nicht empfohlen werden.

[1]  M. Beckmann,et al.  Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study. , 2009 .

[2]  S. Cummings,et al.  The effects of tibolone in older postmenopausal women. , 2008, The New England journal of medicine.

[3]  J. Foidart,et al.  Effect of Tibolone on Breast Cancer Cell Proliferation in Postmenopausal ER+ Patients: Results from STEM Trial , 2007, Clinical Cancer Research.

[4]  L. Delbressine,et al.  Selective Tissue Distribution of Tibolone Metabolites in Mature Ovariectomized Female Cynomolgus Monkeys after Multiple Doses of Tibolone , 2007, Drug Metabolism and Disposition.

[5]  P. Kenemans,et al.  Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. , 2005, Maturitas.

[6]  J. Foidart,et al.  The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double‐blind, placebo‐controlled trial , 2005, BJOG : an international journal of obstetrics and gynaecology.

[7]  A. Keramopoulos,et al.  Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer , 2005, Climacteric : the journal of the International Menopause Society.

[8]  P. Lavín,et al.  Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. , 2004, Fertility and sterility.

[9]  L. Skoog,et al.  A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen–progestogen treatment , 2004, Climacteric : the journal of the International Menopause Society.

[10]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[11]  S. Akinaga,et al.  Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  W. Schoonen,et al.  Receptor profiling and endocrine interactions of tibolone , 2003, Steroids.

[13]  J. Cline,et al.  Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys , 2002, Menopause.

[14]  B. V. VON Schoultz,et al.  Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. , 2002, American journal of obstetrics and gynecology.

[15]  Linda K. Hirota,et al.  Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Kloosterboer.  Tibolone: a steroid with a tissue-specific mode of action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  P. Goodwin,et al.  Risk of menopause during the first year after breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Beral.  Breast cancer and hormone-replacement therapy in the Million Women Study. , 2003, Lancet.